NIH Grant: Tools for Decentralized Clinical Trials in Substance Use Disorder
The National Institutes of Health is offering a grant opportunity titled “Tools for Decentralized Clinical Trials for Substance Use Disorder” (R41/R42 Clinical Trials Optional) to address gaps in decentralized clinical trials for substance use disorders. These trials lack effective sensors for physiological measurements and wearable devices to monitor substances of interest like methadone and buprenorphine. This grant supports small businesses with an award ceiling of $1,972,828, and the application deadline is March 14, 2024.
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DA-25-051 |
| Funding Opportunity Title: | Tools for Decentralized Clinical Trials for Substance Use Disorder (R41/R42 Clinical Trials Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | |
| Expected Number of Awards: | |
| CFDA Number(s): | 93.279 — Drug Abuse and Addiction Research Programs |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Oct 25, 2023 |
| Last Updated Date: | Oct 25, 2023 |
| Original Closing Date for Applications: | Mar 14, 2024 |
| Current Closing Date for Applications: | Mar 14, 2024 |
| Archive Date: | Apr 19, 2024 |
| Estimated Total Program Funding: | |
| Award Ceiling: | $1,972,828 |
| Award Floor: | $ |
Eligibility
| Eligible Applicants: | Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | There are gaps that prevent the utilization of decentralized clinical trials (DCT) in substance use area. The existing sensors for physiological measurement are rarely used and may need further validation. There are no wearable or home-use detection devices on the market capable to measure substances of interest (e.g., methadone, buprenorphine, their metabolites, as well as the spectrum of illicit drugs). The devices in development are not intended for diagnostics or treatment. Most of the devices are intended for laboratory use. Most of the devices do not have standard software interface through which the devices can transmit the data to the study center. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-051.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact: NIH Grants Information
grantsinfo@nih.gov |